When to treat, delay, or omit breast cancer therapy in the face of COVID-19April 10, 2020Breast CancerMetastatic Breast CancerCOVID-19 UpdatesCOVID-19: What's new in heme/oncOncologyWomen's Health
CLEOPATRA: Pertuzumab has long-term benefit in HER2+ breast cancerMarch 27, 2020Breast CancerMetastatic Breast Cancer
HRQOL deteriorates after disease progression in metastatic cancerMarch 11, 2020Patient & Survivor CareLung CancerGastroenterologyBreast CancerGenitourinary CancerMixed TopicsMetastatic Breast Cancer
FDA approves neratinib in combination for metastatic HER2-positive breast cancerFebruary 27, 2020Breast CancerFDA ActionsMetastatic Breast Cancer
Metastatic breast cancer lesions immunologically depleted compared with primarySeptember 17, 2018Breast CancerMetastatic Breast Cancer
FDA expands indication for ribociclib for advanced breast cancerJuly 18, 2018Breast CancerMetastatic Breast Cancer
FDA approves abemaciclib for advanced breast cancerSeptember 28, 2017Breast CancerMetastatic Breast Cancer
HER2 status differed between primary tumor and CTCs in 18.8% of women with MBCSeptember 28, 2017Breast CancerMetastatic Breast Cancer
VIDEO: Dr. William J. Gradishar shares breast cancer take-aways from ASCO 2017June 20, 2017Breast CancerMetastatic Breast Cancer
VIDEO: NCI estimation of MBC numbers a start, but more is neededJune 16, 2017Breast CancerMetastatic Breast Cancer
VIDEO: Metastatic Trial Search links MBC patients to relevant trialsJune 14, 2017Breast CancerMetastatic Breast Cancer
